In conclusion, within the liver, GLP‐1RA is likely to alleviate MASLD indirectly through activation of GLP‐1R on the LSECs, rather than directly affecting hepatocytes (Figure 5H). The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.